Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response
Spatially resolved proteomic, Alternative proteins, Protein mutations, FFPE tissues, Fimbria, p53 signature, STIL, STIC, HGSC, Ovarian cancer, SpiderMass, lipids, FASN, FADH
Spatial proteomic, MALDI MSI, Breast cancer, Psychohistory, Clonal heterogeneity, Therapy